Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuki Tsuji

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Prognostic significance of skeletal muscle mass in patients with alcohol-related cirrhosisAkihiko Shibamoto, Tadashi Namisaki, Satoshi Iwai, et al.
International Journal of Molecular Sciences|April 5, 2020
Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of SteatohepatitisTakahiro Ozutsumi, Tadashi Namisaki, Naotaka Shimozato, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 13, 2023
Hemoglobin levels as a surrogate marker of sarcopenia in patients with liver cirrhosisAkihiko Shibamoto, Tadashi Namisaki, Junya Suzuki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Fibrosis stage is an independent predictor of liver-related complications in primary biliary cholangitisYukihisa Fujinaga, Tadashi Namisaki, Yuki Tsuji, et al.
Digestive Diseases and Sciences|January 20, 2024
VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in CirrhosisShohei Asada, Tadashi Namisaki, Kosuke Kaji, et al.
International Journal of Molecular Sciences|May 14, 2025
Clinical Significance of Marginal Zinc Deficiency as a Predictor of Covert Hepatic Encephalopathy in Patients with Liver CirrhosisTakuya Matsuda, Tadashi Namisaki, Akihiko Shibamoto, et al.
Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology|March 13, 2022
Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosisTadashi Namisaki, Kosuke Kaji, Naotaka Shimozato, et al.
Digestive Diseases and Sciences|March 12, 2025
Risk Factors for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Hepatocellular CarcinomaYuki Tsuji, Tadashi Namisaki, Hiroaki Takaya, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 10, 2019
Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosisNaotaka Shimozato, Tadashi Namisaki, Kosuke Kaji, et al.
In Vivo (Athens, Greece)|April 27, 2023
Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in JapanNobuyuki Yorioka, Tadashi Namisaki, Akihiko Shibamoto, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Prognostic significance of skeletal muscle mass in patients with alcohol-related cirrhosisAkihiko Shibamoto, Tadashi Namisaki, Satoshi Iwai, et al.
International Journal of Molecular Sciences|April 5, 2020
Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of SteatohepatitisTakahiro Ozutsumi, Tadashi Namisaki, Naotaka Shimozato, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|April 13, 2023
Hemoglobin levels as a surrogate marker of sarcopenia in patients with liver cirrhosisAkihiko Shibamoto, Tadashi Namisaki, Junya Suzuki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Fibrosis stage is an independent predictor of liver-related complications in primary biliary cholangitisYukihisa Fujinaga, Tadashi Namisaki, Yuki Tsuji, et al.
Digestive Diseases and Sciences|January 20, 2024
VWF/ADAMTS13 Ratio as a Potential Predictive Biomarker for Acute Kidney Injury Onset in CirrhosisShohei Asada, Tadashi Namisaki, Kosuke Kaji, et al.
International Journal of Molecular Sciences|May 14, 2025
Clinical Significance of Marginal Zinc Deficiency as a Predictor of Covert Hepatic Encephalopathy in Patients with Liver CirrhosisTakuya Matsuda, Tadashi Namisaki, Akihiko Shibamoto, et al.
Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology|March 13, 2022
Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosisTadashi Namisaki, Kosuke Kaji, Naotaka Shimozato, et al.
Digestive Diseases and Sciences|March 12, 2025
Risk Factors for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Hepatocellular CarcinomaYuki Tsuji, Tadashi Namisaki, Hiroaki Takaya, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 10, 2019
Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosisNaotaka Shimozato, Tadashi Namisaki, Kosuke Kaji, et al.
In Vivo (Athens, Greece)|April 27, 2023
Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in JapanNobuyuki Yorioka, Tadashi Namisaki, Akihiko Shibamoto, et al.
Pageof 11